StockMarketWire.com - Bio-pharmaceutical company Motif Bio said it would present data on its wound treatment at an industry conference in San Francisco.

The data for its iclaprim treatment would be presented at IDWeek from 4-7 of October.

The data showed that iclaprim was non-inferior to vancomycin, the company said.

At 1:39pm: [LON:MTFB] Motif Bio Plc Ord 1p share price was -0.6p at 34.4p



Story provided by StockMarketWire.com